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ABSTRACT
Objective: The goal of this research was to determine the
cost-effectiveness of ciproﬂoxacin 0.3%/dexamethasone
0.1% (CD) otic suspension versus oﬂoxacin 0.3% otic solu-
tion (OFX) for treatment of acute otitis media in tympanos-
tomy tube patients.
Methods: A decision-analytic model was used to emulate the
ototopical treatment of acute otitis media in patients with
tympanostomy tubes. The economic outcome was the cost
per otorrhea-free day (OFD) achieved per episode of care.
Three tiers of antimicrobial therapy were modeled, with each
successive tier representing the retreatment of clinical failures
from the preceding tier. First-tier therapy compared CD and
OFX using outcome measures obtained from a randomized
clinical trial (n = 599). Second-tier therapy modeled the use
of amoxicillin/clavulanate (ACA) using outcome measures
obtained from a physician survey and medical literature.
Third-tier therapy was modeled as pathogen-speciﬁc and cur-
ative. It could follow one of three pathways: 1) intramuscular
ceftriaxone; 2) oral ﬂuconazole; or 3) hospitalization for
intravenous antibiotics. Third-tier outcomes were based on a
physician survey. Cost data were obtained from standard ref-
erences and presented from a payer perspective.
Results: The expected therapeutic costs were $249.40 for
the CD pathway and $265.44 for the OFX pathway. The
estimated number of OFDs per episode of care was 25.88 for
the CD pathway and 23.86 for the OFX pathway. The cost-
effectiveness ratios for CD and OFX therapies were $9.64
and $11.13 per OFD, respectively.
Conclusion: CD is both more effective and less costly than
OFX for the treatment of acute otitis media in patients with
tympanostomy tubes.
Keywords: ciproﬂoxacin, cost-effectiveness, decision analy-
sis, dexamethasone, oﬂoxacin, otorrhea, tympanostomy.
Introduction
Acute otitis media in children with tympanostomy
tubes (AOMT) is a potentially serious infection of the
inner ear and a major concern for physicians [1,2].
Currently, oﬂoxacin 0.3% otic solution (OFX) and
ciproﬂoxacin 0.3% and dexamethasone 0.1% otic sus-
pension (CD) are the only ototopical antibiotic prep-
arations approved by the FDA for AOMT. Because
these two agents differ substantially in both their costs
and therapeutic properties, the goal of this research
was to compare their relative cost-effectiveness for
AOMT therapy.
Background
Acute otitis media (AOM) is the most common infec-
tion occurring in children in the United States [3]. In
cases of recurrent AOM tympanostomy tubes are sur-
gically implanted in the eardrum of children to relieve
painful symptoms and prevent potential complica-
tions. As a result of the high incidence of AOM
approximately 500,000 to 2 million tympanostomy
tubes are implanted annually in the United States [4].
Once implanted, tympanostomy tubes usually remain
in place for 12 to 18 months. AOMT is the continued
occurrence of middle ear infections in children despite
the presence of tympanostomy tubes [5]. An estimated
74% of tympanostomy tube patients will still experi-
ence two to six episodes of AOM while the tubes are in
place [6–10]. The cardinal sign of AOMT is a purulent
discharge (otorrhea), which seeps through the tubes
and out the ear canal. Because the presence of otorrhea
indicates AOMT and its resolution denotes a cure,
these two terms (otorrhea and AOMT) will be used
interchangeably.
A literature review failed to identify any accepted
guidelines for treating AOMT. Nevertheless, the
review did indicate that certain AOMT practice pat-
terns exist. Typically, physicians initiate therapy with
an ototopical ﬂuoroquinolone [4,11]. If otorrhea per-
sists past several days, oral antibiotics are usually
added [4–11]. If otorrhea continues despite the addi-
tion of oral antibiotic therapy, the administration of
intramuscular or intravenous antibiotics may be nec-
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essary to resolve the infection [8,12,13]. Although hos-
pitalization for AOMT occurs infrequently, it is
occasionally required for refractory cases [4,8,11].
The  objective  of  AOMT  treatment  is  to  resolve
the underlying infection responsible for the otorrhea.
Therefore, the length of time between the initiation of
therapy and the cessation of otorrhea is an objective,
clinically relevant measure of effectiveness [14]. For
the measure of effect, we opted to use the mathemat-
ical compliment of the duration of otorrhea, that is,
the number of otorrhea-free days (OFDs) per episode
of AOMT care. The episode of care length was based
on the sequential dosing regimens of the drugs in the
clinical algorithm, which totaled 31 days. Utilizing this
information, we designed the present study to compare
the cost-effectiveness of CD and OFX for the treat-
ment of pediatric AOMT.
Methods
We applied a decision-analytic cost-effectiveness
model to compare the expected costs and outcomes of
the only two ototopical drug products approved by the
FDA for treatment of AOM in pediatric patients with
tympanostomy tubes (AOMT). Model development is
discussed in detail in the following sections.
Economic Model
The decision-analytic cost-effectiveness model was
constructed using TreeAge Pro software (Version 5.1,
Treeage Software, Inc., Williamstown, MA, USA). The
analysis was conducted from a third-party payer per-
spective. Only the direct costs of therapy, expressed in
year-2004 US dollars, were considered. The 31-day
model timeline was based on the sequential antibiotic
dosing regimens of the clinical algorithm. This 31-day
period represents an estimate of the time necessary to
fully eradicate otorrhea including the treatment of
refractory patients. Obviously, the actual length of an
AOMT episode of care is highly variable. Neverthe-
less, the rationale for the episode length was based on
the assumption that AOMT caregivers (parents) are
vigilant and compel physicians to treat refractory cases
in a timely manner.
For clarity the following terms are operationally
deﬁned:
• An episode of care equals 31 days; this represents
the cumulative amount of time presented in the
clinical algorithm;
• The duration of otorrhea is the cumulative length
of time that otorrhea persists after initiation of
therapy;
• OFDs are number of days that patients were otor-
rhea-free per episode of care.
OFDs = 31 day episode of care minus the
cumulative duration of otorrhea 
• Cure rate—the percent (or proportion) of patients
otorrhea-free at the end of each tier of therapy.
The cost and effectiveness values for the alternative
treatment pathways were calculated using the follow-
ing formulas:
Therapeutic cost = Σ (cost of each therapeutic 
path × path probability)
Therapeutic effectiveness = Σ (OFDs per therapeutic 
path × path probability)
Cost-effectiveness ratio = Σ therapeutic cost/Σ thera-
peutic effectiveness
Clinical  algorithm. The otorrhea clinical algorithm
consists of three tiers of antimicrobial therapy (Fig. 1).
Each tier has three key elements: 1) the costs of treat-
ment; 2) therapeutic effectiveness, that is, number of
OFDs achieved; and lastly 3) the cure rate, that is, the
proportion of patients cured in each tier of therapy.
The cost of treatment includes antibiotic, physician,
hospital, and laboratory costs. First-tier therapy con-
trasts the use of CD and OFX. Second-tier therapy
models the use of amoxicillin/clavulanate (ACA) to
retreat ﬁrst-tier failures. The third-tier therapy models
the retreatment of second-tier failures and can follow
one of three possible pathways: 1) oral ﬂuconazole; 2)
intramuscular ceftriaxone; or 3) intravenous antibiot-
ics delivered in a hospital inpatient setting. Except for
the ﬁrst-tier of therapy, the model pathways are sym-
metrical in both costs and outcomes. Figure 1 illus-
trates the decision-analytic economic model based on
the clinical algorithm. For more information on the
development of the clinical algorithm refer to an ear-
lier article by Roland et al. [1].
First-Tier Therapy
Costs for physician ofﬁce visits were taken from the
2004 Healthcare Consultants Physicians’ Fee and
Coding Guide [15]. Physician ofﬁce visit costs accrued
at each sequential tier of therapy up to a maximum of
three visits. Physician ofﬁce visit cost was set at $69.00
based on the reimbursement rates for the evaluation
and maintenance of both new and established patients
(current procedural terminology codes [CPT] 99201–
99203 and 99211–99213) [15]. OFX and CD costs
were based on 2004 Drug Topics Red Book average
wholesale prices (AWP). The AWP for a 5-mL package
of OFX was $48.48 and the AWP for a 7.5-mL pack-
age of CD was $87.80 [16].
The duration of otorrhea and cure rates for CD
and OFX were obtained from caregiver diary records
taken on 599 children who participated in a masked
randomized multisite clinical trial conducted in the
United States and Canada [14]. The trial subjects
were children, aged 6 months to 12 years, with patent
tympanostomy tubes and a clinical diagnosis of otor-
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rhea in one or both ears for 3 weeks duration or less.
Subjects received either CD (four drops twice daily
for 7 days) or OFX (ﬁve drops twice daily for
10 days). Caregivers documented the presence or
absence of otorrhea each morning and evening. Diary
compliance rates were 98.9% and 99.3% for the CD
and OFX groups, respectively. The duration of otor-
rhea represents as the longest period of otorrhea
observed in either ear. The cure rate was deﬁned as
the proportion of patients documented as otorrhea-
free after 7 days of therapy. First-tier cure rates and
mean durations of otorrhea were calculated using a
Kaplan–Meier survival analysis (Fig. 2). A log-rank
statistic was used to test the CD and OFX survival
functions for homogeneity. The proportion children
documented with otorrhea that persisted past 7 days
of treatment represent the clinical failures that pro-
ceed to second-tier therapy.
Second-Tier Therapy
Although oral ACA is not approved by the FDA for
treatment of otorrhea, it was chosen as the second-
tier antibiotic for several reasons. First, ACA is the
antibiotic recommended by the American Academy
of Pediatrics for the retreatment of AOM therapeu-
tic failures [3,17]. Second, ACA was the antibiotic
chosen for the retreatment of initial ototopical treat-
ment failures in an earlier physician practice pattern
survey [1]. We found only one study where ACA
was used to treat otorrhea in children with tym-
panostomy tubes [18]. In that study the authors
reported an ACA cure rate of 69%. We used that
Figure 1 Otorrhea (acute otitis media in tympanostomy tube [AOMT]) therapeutic decision-analytic model. ACA, amoxicillin/clavulanate; C&S, culture
and sensitivity; CD, ciproﬂoxacin/dexamethasone; OFX, oﬂoxacin.
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value (69%) as our second-tier ACA effectiveness
rate. The cost of ACA was set at $58.44. We derived
this estimate from the average of Red Book AWPs
for various package sizes of reconstitutable ACA
powder for oral suspension from four different man-
ufacturers. Package size determination was based on
a dosing regimen of amoxicillin 40 mg/kg per day
for 10 days for a 15-kg child [16,19]. When the Red
Book presented multiple repackagers of a product,
the mean AWP of all repackagers was used as the
representative drug cost.
The number of OFDs for second-tier and third-tier
therapy was based on a survey of 41 physicians from a
variety of geographic locations and various practice
settings. The surveyed physicians included medical
school faculty, family practitioners, otolaryngologists,
and pediatricians. These physicians were selected
because, in our opinion, they possessed greater than
average experience in treating tympanostomy tube
otorrhea. The survey consisted of four brief AOMT
clinical vignettes appropriate for the clinical algorithm.
The physicians were asked to estimate the time neces-
sary to achieve an otorrhea-free state for the four clin-
ical vignettes. We speciﬁcally asked the physicians to
estimate the shortest, average, and longest time
expected for each drug in the vignettes to resolve the
otorrhea.
The second-tier therapeutic vignette is presented
below:
Joey is a 4-year-old white male whose otorrhea has
failed to resolve after an initial 7-day course of an
ototopical ﬂuoroquinolone. On otoscopic examina-
tion, the tympanostomy tubes appear patent. You
are uncertain as to cause of the treatment failure,
but you suspect it could be either a) a compliance
problem; b) failure of the ototopical agent to pen-
etrate the tubes; or c) resistant microorganisms.
You prescribe Augmentin ES-600 oral suspension,
45 mg/kg twice a day for 10 days with instructions
to administer the medication until the entire course
of therapy has been completed.
Sixty-six percent of the physicians (n = 27)
responded to the survey.
Third-Tier Therapy
The number of OFDs for third-tier therapies was also
estimated from the physician survey. Third-tier antibi-
otic choices were based on the microbiologic spectrum
of treatment failures from the aforementioned clinical
trial [14]. Third-tier therapy was modeled as being
pathogen-speciﬁc thus accruing costs for microbial cul-
ture and sensitivity testing (C&S). Because third-tier
therapy was modeled as pathogen-speciﬁc all patients
were considered cured on completion of the algorithm.
C&S costs were obtained from the 2004 MAG Mutual
Healthcare Consultants Physicians’ Fee and Coding
Guide [15]. The cost for the culture was $38.00 (CPT
87070) and the cost for the antimicrobial susceptibility
analysis was $26.00 (CPT 87184), for a total of
$64.00 [15].
Fifty-one patients were label as treatment failures in
the AOMT clinical trial [1]. Of these failures, 41%
(n = 21) tested positive for Candida sp. Therefore,
41% of the third-tier patients were modeled as receiv-
ing oral ﬂuconazole [19,20]. The cost of oral ﬂucona-
zole was based on a dosing regimen of 3 mg/kg per day
for 14 days for a 15-kg child [19,20]. This regimen
requires two packages of ﬂuconazole 350-mg powder
for oral suspension (Diﬂucan, Pﬁzer Inc., New York,
NY, USA) with an AWP of $38.40 each, for a total
drug cost of $76.80 [16].
Thirty-seven percent (n = 19) of the clinical trial
treatment failures patients tested positive for either
Escherichia coli, Haemophilus inﬂuenzae, Moraxella
catarrhalis, Staphylococcus epidermidis, Streptococcus
pneumoniae, Staphylococcus sp., or Streptococcus sp.
[1]. Therefore, 37% of the third-tier patients were
modeled as receiving intramuscular ceftriaxone (Roce-
phin, Roche Laboratories Inc., Nutley, NJ, USA).
Ceftriaxone was chosen for its efﬁcacy and because its
intramuscular route of administration overcomes
issues of noncompliance [19,20]. The ceftriaxone reg-
imen was based on 50 mg/kg per day for a 15-kg child
given intramuscularly for 3 days [19,20]. This regimen
requires three 1-g ceftriaxone single-use vials and three
intramuscular injection fees. The 2004 AWP for a 1-g
ceftriaxone single-use vial was $54.68 based on the
AWPs from three separate suppliers. The intramuscu-
lar administration fee was set at $24.00 based on the
2004 MAG Mutual Healthcare Consultants Physi-
cians’ Fee and Coding Guide CPT code of 90788 [15].
Therefore, the total cost for ceftriaxone therapy was
set at $236.04.
Lastly, 22% (n = 11) of the clinical trial treatment
failures tested positive for one or more of the following
pathogens: Corynebacterium amycolatum, Pseu-
domonas aeruginosa, or Staphylococcus aureus. These
pathogens are generally susceptible to either vancomy-
cin, penicillinase-resistant penicillins, extended-spec-
trum penicillins or aminoglycosides all of which
require intravenous administration [19,20]. Conse-
quently, 22% of the third-tier patients were modeled
as needing treatment in a hospital setting. The cost of
hospitalization for otorrhea was set at $6080.00. This
cost was based on the year-2000 Healthcare Cost and
Utilization Project (HCUP) charge for inpatients of
17 years of age or younger diagnosed with otitis media
and upper respiratory tract infections (diagnostic-
related group [DRG] code 70) [21]. Year-2000 costs
were adjusted to year-2004 costs using US Bureau of
Labor Statistics consumer price index values for hos-
pital inpatient services [22].
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Results
A Kaplan–Meier survival analysis of the caregiver dia-
ries established the mean durations of otorrhea for the
CD and OFX groups at 3.15 days and 4.24 days,
respectively. Recall that the number of OFDs equals
31 days (the episode length) minus the duration of
otorrhea. Consequently, the number of OFDs attrib-
uted to the cured proportions of the CD and OFX
groups in tier one was 27.86 and 26.76 days, respec-
tively (Table 1). A log-rank test established that the 7-
day survival curves between the CD and OFX groups
were signiﬁcantly different (P ≤ 0.001). After 7 days of
treatment 85% of the CD patients were documented as
otorrhea-free compared with only 76% in the OFX
group. Figure 2 contrasts the survival (otorrhea-free)
curves between the ototopical treatment groups.
The second-tier cure rate, deﬁned as the percent of
subjects otorrhea-free after 10 days of ACA therapy,
was modeled at 69% based on evidence found in the
medical literature [18]. Based on the physician survey
the number of OFDs for successful second-tier therapy
was estimated at 17.88 days. Because third-tier ther-
apy was modeled as pathogen-speciﬁc, it was consid-
ered 100% curative. The physicians estimated the
number of OFDs for the ﬂuconazole, ceftriaxone and
hospital pathways at 5.78, 9.09 and 8.58, respectively.
Populating the decision-analytic cost-effectiveness
model (Fig. 1) with the cost and outcome estimates
generated an expected otorrhea treatment cost of
$249.40 for CD and $265.44 for OFX (Table 2).
Additionally, the model generated an expected out-
come of 25.88 OFDs for CD patients compared with
only 23.86 OFDs for OFX patients per episode of care.
The resultant cost-effectiveness ratios are $9.64 and
$11.13 for CD and OFX therapies, respectively
(Table 2).
The results indicate that CD therapy economically
dominates OFX therapy for the treatment of otorrhea
in tympanostomy tube patients, that is, CD is both
more effective and less costly.
Sensitivity Analyses
We performed one-way, two-way, and best case, likely
case, worst case sensitivity analyses to determine the
robustness of the economic model. In the one-way sen-
sitivity analysis we varied all model parameters across
their respective 95% conﬁdence intervals with the
exceptions of the cost estimates and the ACA cure rate,
which we varied by ± 5%. The one-way sensitivity
analysis revealed no cost-effectiveness thresholds indi-
cating that the model was robust within the parame-
ters tested.
In the two-way sensitivity analysis we varied CD
and OFX costs to examine the effect. The results are
presented in Fig. 3. The two-way sensitivity graph
illustrates the relative expected costs and expected
cost-effectiveness thresholds of the two comparators at
various cost estimates. The vertical axis represents
OFX acquisition costs ranging from $18.00 to $48.00.
The horizontal axis represents CD acquisition costs
ranging from $78.00 to $88.00. The interface of the
diagonal and checked patterns represents the cost
threshold of the two ototopical alternatives at their
various cost levels. For all ordered cost pairs falling
above the interface CD represents the better value and
Table 1 Duration of otorrhea (DO) and otorrhea-free days
(OFDs) values for modeled case, best case, likely case, and worst
case sensitivity analysis
Drug Tier Case
Cumulative
DO
Number
of OFDs
CD First Modeled 3.14 27.86
Best 2.89 28.11
Likely 3.14 27.86
Worst 3.40 27.60
OFX First Modeled 4.24 26.76
Best 4.00 26.00
Likely 4.24 26.76
Worst 4.49 26.51
ACA Second Modeled 13.12 17.88
Best 9.78 21.22
Likely 11.89 19.11
Worst 17.70 13.30
Ceftriaxone Third Modeled 21.91 9.09
Best 19.17 11.83
Likely 21.15 9.85
Worst 25.41 5.59
Fluconazole Third Modeled 25.22 5.78
Best 21.31 9.69
Likely 24.17 6.83
Worst 30.60 0.40
Hospital Third Modeled 22.42 8.58
Best 19.73 11.27
Likely 21.62 9.38
Worst 25.92 5.08
ACA, amoxicillin/clavulanate; CD, ciproﬂoxacin/dexamethasone; OFX, oﬂoxacin
otic.
Table 2 Otorrhea therapy cost-effectiveness (C/E) results
Strategy Cost ($)
Incremental
cost ($)
Effect 
(OFDs)
Incremental 
effect (OFDs)
C/E ratio
($)
Incremental 
C/E ratio (ICER)
CD 249.40 25.88 9.64
OFX 265.44 16.04 23.86 −2.02 11.13 (Dominated)
All results rounded to the nearest integer.
CD, ciproﬂoxacin/dexamethasone; OFDs, otorrhea-free days; OFX, oﬂoxacin otic.
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OFX represents the better value for all ordered cost
pairs falling below the pattern interface. The diagonal
line below and parallel to the pattern interface repre-
sents the cost-effectiveness threshold. Here again for
all ordered cost pairs falling above the line CD repre-
sents the more cost-effective alternative and OFX rep-
resents the more cost-effective option for all ordered
cost pairs falling below the cost-effectiveness line.
Additionally, we performed a best case, likely case,
worst case scenario sensitivity analysis and compared
the results to the modeled outcomes. The physician
survey was speciﬁcally designed to provide estimates to
address these three scenarios. We also simultaneously
varied the cost parameters in a manner that potenti-
ated the best, likely, and worst case scenarios. For
example, in the best case scenario the largest OFD esti-
mates were used in conjunction with the 95% cost esti-
mates, that is, the quickest time to cure and the lowest
drug costs, were used to generate the outcomes. In the
worst case scenario the opposite assumptions were
applied; the shortest OFD estimates were used in con-
junction with the 105% cost estimates to generate the
outcomes.
The results for best case, likely case, and worst case
scenarios are shown in Table 3. The results of each sce-
nario reiterate that CD is more cost-effective than
OFX for the treatment of AOMT. In the best case sce-
nario, the cost-effectiveness ratios for CD and OFX
were $7.71 and $8.46 per OFD, respectively. In the
likely case scenario, the cost-effectiveness ratios for
CD and OFX were $9.64 and $11.13, respectively. In
the worst case scenario, the cost-effectiveness ratios for
CD and OFX were $10.70 and $14.94, respectively.
All three sensitivity scenarios reafﬁrmed CD’s eco-
nomic dominance over OFX, yielding an average cost
savings of $2.14 per OFD.
Discussion
Given the concern of rising health-care costs decision-
makers are under mounting pressure to reduce
expenses and yet maintain a high standard of patient
care. The ambition of limiting therapeutic costs while
optimizing patient outcomes mandates the replace-
ment of inefﬁcient therapies with more cost-effective
alternatives. Health economic models such as the deci-
sion-analytic model presented in this study, which
compare the cost and efﬁcacy data of relevant alterna-
tives, can facilitate decision-makers in the therapeutic
selection process.
Although ﬁrst-tier therapy with CD appears more
expensive because of its higher acquisition costs, the
clinical algorithm and economic model demonstrate
that, for the population of children with otorrhea,
treatment with CD is ultimately more cost-effective
because of its better efﬁcacy. The cost savings gener-
ated from averted retreatment coupled with CD
patients’ higher number of OFDs offset the economic
gain from OFX’s lower acquisition cost. Sensitivity
analyses indicate the model is robust with respect to
variations in the model parameters and generated
Figure 3 Two-way sensitivity analysis of CD and OFX costs. CD, cipro-
ﬂoxacin/dexamethasone; OFX, oﬂoxacin otic.
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Table 3 Best case, likely case, and worst case cost-effectiveness ratios
Therapy Cost ($)
Incremental
cost ($)
Effect 
(OFDs)
Incremental 
effect (OFDs)
Cost-effectiveness
ratio ($/OFD)
Best case scenario
CD 208.39 27.02 7.71
OFX 214.49 6.10 25.34 −1.68 8.46
Likely case scenario
CD 249.40 25.88 9.64
OFX 265.40 16.00 23.86 −2.02 11.13
Worst case scenario
CD 269.10 25.16 10.70
OFX 326.30 57.20 21.84 −3.32 14.94
CD, ciproﬂoxacin/dexamethasone; OFX, oﬂoxacin otic; OFDs, otorrhea-free days.
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consistent economic results. Simply put, CD is less
costly than OFX per episode of otorrhea and produces
better clinical outcomes.
Although this analysis resembles our earlier eco-
nomic comparison of CD and OFX it differs in several
important aspects. Our earlier AOMT economic study
contained no effectiveness measure per se and was
essentially a cost-minimization analysis. Also our ear-
lier AOMT economic model was developed before CD
was released and consequently there was no CD cost
information available. In the absence of a CD cost esti-
mate we used the price of OFX as a reference cost
for CD and performed a breakeven analysis. The
breakeven cost of CD was expressed as a multiple of
the OFX reference. In this study we populated the eco-
nomic model with both a CD cost and a measure of
effectiveness (OFDs). Consequently, this research is a
cost-effectiveness analysis as opposed to our earlier
cost-minimization study. Other important differences
between this study and our earlier work include dif-
ferent assessment of the ﬁrst-tier cure rates. Both the
timing and perspective of the ﬁrst-tier cure rates have
been revised. In our earlier study the ﬁrst-tier ototop-
ical cure rates were assessed 11 days after therapy was
initiated. In this study ﬁrst-tier cure rates were assessed
7 days after the start of therapy. The decision to shift
assessment time from 11 to 7 days was driven by the
recommended dosing regimens of the ﬁrst-tier drugs.
CD has a recommended 7-day AOMT dosing regimen
compared with 10 days for OFX. Lastly and perhaps
most importantly, in this study the ototopical cure rate
was determined by the patient’s caregivers, usually the
patient’s mothers, as opposed to the physicians in our
earlier economic evaluation. Considering that AOMT
is an acute infection typically treated in the ambulatory
setting caregiver assessment of ﬁrst-tier therapy is
more representative of actual clinical practice than
physician assessment. Overall we believe this research
represents a substantial reﬁnement of our previous
economic assessment of ototopical AOMT therapy.
Limitations
The results of our study were limited by the use of clin-
ical trial efﬁcacy data combined with the clinical liter-
ature and a physician survey as opposed to real-world
effectiveness data. Because of the ideal conditions asso-
ciated with clinical trials, which are rarely encountered
in actual practice, the efﬁcacy results may overestimate
the true effectiveness of either of the interventions
under study. Another limitation was the use of refer-
ence-based price estimates instead of actual cost data.
We realize there is substantial cost variation for similar
products and services within the United States, and
understand the advantages of using actual cost data in
economic analyses when available. Given this fact, it’s
extremely difﬁcult to obtain actual prices for one hos-
pital or provider, much less several, because of incen-
tive-based and other contract agreements with
suppliers. To overcome these limitations, we per-
formed extensive sensitivity analyses, which supported
the robustness of the model to changes in key
parameters.
The clinical algorithm assumes that the ACA cure
rates are the same for each pathway regardless of the
initial ototopical therapy. Although this is a logical
postulation based on the molecular similarities of the
ﬁrst-tier ﬂuoroquinolones, we have no empirical evi-
dence to support this premise. Given that the ﬁrst-tier
ototopical agents exhibit different rates of clinical suc-
cess, it is entirely possible that the assumed ACA cure
rates may differ depending on the initial ﬂuoroqui-
nolone chosen. Consequently, we acknowledge that
this is a limitation for this economic model.
Conclusions
CD is preferred to OFX for the initial treatment of chil-
dren with otorrhea. The superior efﬁcacy of CD makes
it more cost-effective than OFX in the management of
otorrhea in children with tympanostomy tubes. Over-
all CD costs less per episode of otorrhea and produces
better clinical outcomes. Therefore, patients, caregiv-
ers, physicians, and healthcare payers all beneﬁt from
the use of CD for initial otorrhea therapy.
Source of ﬁnancial support: Curtis Waycaster, Michael Wall,
and Jeffrey Glass are employed by Alcon Laboratories Inc.
Alcon is the sole proprietor of ciproﬂoxacin dexamethasone
combination agent modeled in the study. Peter Roland has
been a paid consultant for Alcon in the past; however, he was
not directly compensated for this article.
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